Cooley advised Akeso, Inc. on the offering. Akeso, Inc. (Hong Kong Exchange code: 9926.HK), a commercial-stage biopharmaceutical company, announced its HK$1.2 billion (appr. USD$153.29 million) follow-on public...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
